Lv4 Is a Capsid-Specific Antiviral Activity in Human Blood Cells That Restricts Viruses of the SIV_MAC/SIV_SM/HIV-2 Lineage Prior to Integration

• Massimo Pizzato,

  Affiliations Department of Microbiology and Molecular Medicine, University of Geneva, Geneva, Switzerland, Center for Integrative Biology, University of Trento, Trento, Italy

  ⨯
• Sean Matthew McCauley,

  Affiliation Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America

  ⨯
• Martha R. Neagu,

  Affiliation Department of Microbiology and Molecular Medicine, University of Geneva, Geneva, Switzerland

  ⨯
• Thomas Pertel,

  Affiliation Department of Microbiology and Molecular Medicine, University of Geneva, Geneva, Switzerland

  ⨯
• Claudia Firrito,

  Affiliation Department of Microbiology and Molecular Medicine, University of Geneva, Geneva, Switzerland

  ⨯
• Serena Ziglio,

  Affiliation Center for Integrative Biology, University of Trento, Trento, Italy

  ⨯
• Ann Dauphin,

  Affiliation Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America

  ⨯
• Madeleine Zufferey,

  Affiliation Department of Microbiology and Molecular Medicine, University of Geneva, Geneva, Switzerland

  ⨯
• Lionel Berthoux,

  Affiliation Laboratory of Retrovirology, University of Québec, Trois-Rivières, Quebec, Canada

  ⨯
• Jeremy Luban

  * E-mail: jeremy.luban@umassmed.edu

  Affiliations Department of Microbiology and Molecular Medicine, University of Geneva, Geneva, Switzerland, Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America

  ⨯